Neuroendocrine Tumors Clinical Trials in Philadelphia, Pennsylvania

7 studies are recruiting for neuroendocrine tumors in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

   This Phase 1/2, multicenter, open-label, FIH study aims to evaluate the safety, tolerability, PK, and preliminary antitumor activity of CRN09682 in participants with SST2-expressing NENs and other solid tumors. The study includes a Dose Escalation Phase to determine the MTD and DLTs. Following MTD …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Crinetics Study Site, Philadelphia, Pennsylvania

   Locations

   27 in total

   Run by

   Crinetics Pharmaceuticals Inc.

   See if you can join NCT07129252 on ClinicalTrials.gov

2. Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

   This is a multi-site, three-cohort phase II trial of cabozantinib for IMDC all-risk frontline metastatic renal cell carcinoma (mRCC) patients OR any line mRCC patients who have not previously been treated with cabozantinib, and patients with pancreatic or extra-pancreatic neuroendocrine tumors.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Fox Chase Cancer Center, Philadelphia, Pennsylvania

   Run by

   Fox Chase Cancer Center

   See if you can join NCT05263050 on ClinicalTrials.gov

3. CapTemY90 for Grade 2/3 NET Liver Metastases

   This is a Phase 2 evaluation of hepatic-progression free survival among patients with Grade 2 liver-dominant NET metastases undergoing combination therapy with CapTem and Y90 radioembolization.The hypothesis is to confirm safety and to assess if disease control is improved relative to expectation f…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   4 in total

   Run by

   Abramson Cancer Center at Penn Medicine

   See if you can join NCT04339036 on ClinicalTrials.gov

4. Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

   This phase 1 study is to determine the optimal dose and tolerability of a hypoxia-activating agent, tirapazamine, when it is combined with embolization in liver cancer. Liver cancer patients who are Child-Pugh score A, suitable for embolization with tumor no more than 4 nodules are eligible. Tirapa…

   Stage

   Phase 1

   Ages

   20 to 99

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   2 in total

   Run by

   Teclison Ltd.

   See if you can join NCT02174549 on ClinicalTrials.gov

5. Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

   This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2 in subjects with inoperable, advanced, well-differentiated,…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Facility, Philadelphia, Pennsylvania

   Locations

   54 in total

   Run by

   RayzeBio, Inc.

   See if you can join NCT05477576 on ClinicalTrials.gov

6. A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

   The goal of this clinical trial is to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least 1 standard treatment regimen in the metastatic or locally advanced setting.

   Stage

   Phase 1

   Ages

   18 to 85

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   4 in total

   Run by

   Chimeric Therapeutics

   See if you can join NCT06055439 on ClinicalTrials.gov

7. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

   International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

   Stage

   Not phased

   Ages

   Any age

   Site

   Massive Bio SYNERGY-AI site, Philadelphia, Pennsylvania

   Locations

   68 in total

   Run by

   Massive Bio, Inc.

   See if you can join NCT03452774 on ClinicalTrials.gov